Liver cancer
Oncology· 5 reviewed drugs· 25176 cited findings behind them
What the regulatory reviews cover
Regulatory review documents for several drugs concerning liver cancer are available in this library. These include Avastin, indicated for Hepatocellular Carcinoma (HCC) in combination with atezolizumab for unresectable or metastatic HCC who have not received prior systemic therapy, with an Overall Survival (OS) Hazard Ratio of 0.58. Stivarga is indicated for Hepatocellular carcinoma (HCC) who have been previously treated with sorafenib, showing an Overall Survival (STIVARGA) of 10.6 months compared to 7.8 months for Placebo. Imjudo is indicated for the first-line treatment of adults with advanced or unresectable hepatocellular carcinoma (HCC), with a Median OS for sorafenib vs placebo in advanced HCC of 10.7 vs 7.9 months. Opdivo's indication includes MSI-H or dMMR metastatic colorectal cancer (mCRC) that has, with an Overall Response Rate (ORR) of 31.7%. Lenvima is indicated for the treatment of patients with locally recurrent or metastatic, progressive, radioactive iodine-refractory differentiated thyroid cancer (DTC), with a PFS Hazard Ratio (Lenvatinib vs Placebo) of 0.21.
It is important to note that these drugs were studied in different clinical trials, and therefore, the reported figures are not directly comparable in a head-to-head manner.
The drugs — one cited result each
| Opdivo Bristol-Myers Squibb Company | Overall Response Rate (ORR): 31.7% BRISTOL MYERS SQUIBB — Opdivo FDA Summary Review (NDA/BLA 12, p.3 |
| Avastin Roche Holding AG | Overall Survival (OS) Hazard Ratio: 0.58 GENENTECH — Avastin FDA Review (NDA/BLA 125085, 2023), p.71 |
| Stivarga Bayer Aktiengesellschaft | Overall Survival (STIVARGA): 10.6 BAYER HLTHCARE — Stivarga FDA Review (NDA/BLA 203085, 2019), p.30 |
| Imjudo AstraZeneca PLC | Median OS for sorafenib vs placebo in advanced HCC: 10.7 vs 7.9 AstraZeneca PLC — Imjudo EMA EPAR public assessment report (, p.12 |
| Lenvima Eisai Co., Ltd. | PFS Hazard Ratio (Lenvatinib vs Placebo): 0.21 EISAI INC — Lenvima FDA Summary Review (NDA/BLA 206947, 2015, p.3 |
Different drugs were studied in different trials — these figures are not head-to-head comparisons.
Explore the full evidence
Every finding behind these drugs — searchable, comparable and answerable in plain language — is in the Oncology research library →
Lists reflect the regulatory review documents in this library, not all therapies that exist. Educational reference only — not medical or investment advice.